Biotie Therapies Selects Bracket's CDR System for Phase II Parkinson's Trial
Published on:
Applied Clinical Trials
Bracket announced that Biotie Therapies has selected its CDR System for use as the primary endpoint for their Phase II trial.
Bracket announced that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected its CDR System for use as the primary endpoint for their Phase II trial of SYN120, an orally administered, dual 5HT6/5HT2a antagonist. SYN120 is in development for the treatment of Parkinson’s disease and other cognitive disorders.
The CDR System, a computerized cognitive testing method, has been used successfully in over 25 therapeutic trials including, but not limited to, Parkinson’s Disease, Alzheimer’s Disease and Mild Cognitive Impairment. It assesses the major domains of cognitive function that are vulnerable to aging, fatigue, disease, pathology, trauma, diet and pharmaceuticals.
